EUVIMEDEUVIMED entdecken
Crossref

Investigating Generation of Antibodies against the Lipid Nanoparticle Vector Following COVID-19 Vaccination with an mRNA Vaccine

Rasmus Münter iD, Erik Sørensen, Rasmus B Hasselbalch, Esben Christensen, Susanne D Nielsen, Peter Garred, Sisse R Ostrowski, Henning Bundgaard, Kasper K Iversen, Thomas L Andresen, Jannik B Larsen iD

Molecular Pharmaceutics · 2023

DOI: 10.1021/acs.molpharmaceut.2c01036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Rasmus Münter und 10 weiteren Autor:innen. Beteiligte Einrichtung: Biotherapeutic Engineering and Drug Targeting, Department of Health Technology, Technical University of Denmark (DTU), Kgs. Lyngby 2800, Denmark. Hauptthemen laut MEDLINE: COVID-19, Nanoparticles, Hypersensitivity. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 64 Literaturangaben. Gefördert von: Svend Andersen Fonden, Novo Nordisk Fonden, Carlsbergfondet.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19NanoparticlesHypersensitivityAdultHumansCOVID-19 VaccinesBNT162 VaccinemRNA VaccinesVaccinationAntibodiesLiposomes

Stichwörter der Autor:innen

COVID-19anti-drug antibodylipid nanoparticlemRNA vaccinepoly(ethylene glycol)side effects

Substanzen

COVID-19 VaccinesBNT162 VaccinemRNA VaccinesAntibodiesLipid NanoparticlesLiposomes

Autor:innen und Institutionen

  • Biotherapeutic Engineering and Drug Targeting, Department of Health Technology, Technical University of Denmark (DTU), Kgs. Lyngby 2800, Denmark.
  • Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen 2100, Denmark.
  • Department of Cardiology, Copenhagen University Hospital Herlev and Gentofte, Copenhagen 2100, Denmark.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2200, Denmark.
  • Viru-immunology Research Unit, Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen 2100, Denmark.
  • Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Copenhagen University Hospital, Rigshospitalet, Copenhagen 2100, Denmark.

ORCID-Profile: Rasmus Münter, Jannik B Larsen

Förderung

  • Svend Andersen Fonden
  • Novo Nordisk Fonden
  • Carlsbergfondet

Zitieren

APA

Münter, R., Sørensen, E., Hasselbalch, R. B., Christensen, E., Nielsen, S. D., Garred, P., Ostrowski, S. R., Bundgaard, H., Iversen, K. K., Andresen, T. L., & Larsen, J. B. (2023). Investigating Generation of Antibodies against the Lipid Nanoparticle Vector Following COVID-19 Vaccination with an mRNA Vaccine. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.2c01036

Vancouver

Münter R, Sørensen E, Hasselbalch RB, Christensen E, Nielsen SD, Garred P, et al. Investigating Generation of Antibodies against the Lipid Nanoparticle Vector Following COVID-19 Vaccination with an mRNA Vaccine. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.2c01036

BibTeX
@article{Mnter2023,
  author = {Münter, Rasmus and Sørensen, Erik and Hasselbalch, Rasmus B and Christensen, Esben and Nielsen, Susanne D and Garred, Peter and Ostrowski, Sisse R and Bundgaard, Henning and Iversen, Kasper K and Andresen, Thomas L and Larsen, Jannik B},
  title = {Investigating Generation of Antibodies against the Lipid Nanoparticle Vector Following COVID-19 Vaccination with an mRNA Vaccine},
  journal = {Molecular Pharmaceutics},
  year = {2023},
  doi = {10.1021/acs.molpharmaceut.2c01036}
}
Kostenlos starten →